Moreover, experimental analysis of The Cancer Genome Atlas database (TCGA) colorectal cancer-associated DLC1 mutant (E966K), whose mutation is adjacent to the 929–957 deletion in DLC1-START, phenocopied these results, as it encoded a protein that was deficient in binding to Caveolin-1 in cells and displayed impaired DLC1 tumor suppressor activities (cell migration and anchorage-independent growth) without affecting its RhoGAP activity [3]. This evidence concerns the gene DLC1 and colorectal cancer.